文献速递中医内科中药与中成药合理使用

心脉康片通过调控SREBP2介导的NLRP3/ASC/Caspase-1通路减轻动脉粥样硬化

Xinmaikang (XMK) tablets alleviate atherosclerosis by regulating the SREBP2-mediated NLRP3/ASC/Caspase-1 signaling pathway.
PubMed 文献 · J Ethnopharmacol · 2023-09-28

本研究探讨心脉康片(XMK)对ApoE-/-小鼠动脉粥样硬化的作用及骨髓来源巨噬细胞(BMDM)中的机制。采用LC-MS/MS分析、分子对接、体内高脂饮食模型(12周造模+12周给药)及体外LPS刺激BMDM实验。结果显示XMK改善血脂、减少斑块面积、抑制炎症因子,并通过下调SREBP2/NLRP3/ASC/Caspase-1通路发挥作用,且未显示心肝肾毒性。

要点

  • 心脉康片可改善ApoE-/-小鼠血脂(TC、TG、LDL-C、HDL-C)并减少动脉粥样硬化斑块面积。
  • XMK抑制炎症因子IL-6、TNF-α、VCAM-1表达,下调SREBP2/NLRP3/ASC/Caspase-1通路。
  • 体外敲低SREBP2可抑制XMK对NLRP3/ASC/Caspase-1通路的调控作用。

核心结论

  • 心脉康片通过SREBP2介导的NLRP3/ASC/Caspase-1信号通路改善炎症,从而抑制动脉粥样硬化。

研究设计与样本

  • 体外实验:LPS刺激的骨髓来源巨噬细胞(BMDM)给予不同浓度XMK(1、2.5、5、10、20、40 μg/ml),并进行免疫荧光、腺病毒感染和siRNA敲低(SREBP2、NLRP3、Caspase-1、ASC)。
  • XMK汤剂采用LC-MS/MS分析,并进行分子对接预测有效成分与SREBP2、NLRP3的相互作用。

主要发现

  • 分子对接显示XMK有效成分与SREBP2和NLRP3稳定结合。
  • 血清酶学(AST/ALT、Cr、LDH、CK-MB)提示XMK对心、肝、肾功能具有用药安全性。
  • 体内实验显示XMK改善血清血脂(TC、TG、LDL-C、HDL-C)、减少斑块面积、降低体重,并抑制炎症因子(IL-6、TNF-α、VCAM-1)表达。
  • XMK下调SREBP2、NLRP3、ASC、IL-1β和Caspase-1的mRNA和蛋白表达。
  • 体外实验强化上述发现,且敲低SREBP2抑制XMK对NLRP3/ASC/Caspase-1通路的效应。

临床怎么用

  • 心脉康片临床用于动脉粥样硬化的防治,本研究表明其可能通过调控SREBP2/NLRP3/ASC/Caspase-1通路改善炎症。
  • 本研究的血清酶学结果支持XMK在心、肝、肾功能方面的用药安全性,但需结合临床进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Xinmaikang (XMK) tablets, a Chinese patent medicine, have been used for the prevention and treatment of atherosclerosis (AS) clinically. However, the underlying mechanism of XMK is far from completely illustrated. AIM OF THE STUDY: This study aimed to determine whether XMK alleviates AS in Apolipoprotein E-knockout (ApoE-/-) mice and to explore the potential mechanism of action in bone marrow-derived macrophages (BMDMs). MATERIALS AND METHODS: XMK decoction was analyzed by an LC‒MS/MS assay. Molecular docking was conducted to determine the interaction of XMK molecular ligands and AS targets. In vivo, 10 ApoE-/- mice were selected as the control group. Fifty ApoE-/- mice were randomly divided into 5 groups: the model group, low-, medium-, and high-dose XMK groups and the simvastatin group. Mice in the control group were fed a chow diet, and the other 5 groups were fed a high-fat diet (HFD) for 12 weeks. After 12 weeks, the treatment groups were administered low-dose XMK (2.28·kg-1·d), medium-dose XMK (4.55·kg-1·d), high-dose XMK (9.1 kg-1 d) and simvastatin (91 mg-1 d) for another 12 weeks. Serum enzymology assays tested AST/ALT, Cr, LDH and CK-MB levels. The atherosclerotic plaques and lipid deposition were measured by Oil red O (ORO) staining and Hematoxylin and Eosin (H&E) staining. Then, we examined the body weight and serum lipids (TC, TG, LDL-C and HDL-C) of the mice. ELISA was performed to determine the levels of inflammatory factors (IL-6, TNF-ɑ, VCAM-1, CXCL8 and CCL2). SREBP2/NLRP3 signaling pathway-related genes (SREBP2, NLRP3, ASC, IL-1β and Caspase-1) were analyzed by RT‒qPCR and western blotting. In vitro, LPS-stimulated BMDMs were treated with different concentrations of XMK (1, 2.5, 5, 10, 20, and 40 μg/ml). Immunofluorescence staining (SREBP2, NLRP3), adenovirus infection and siRNA knockdown (SREBP2, NLRP3, Caspase-1 and ASC) were conducted as complements to the in vivo experiment. RESULTS: Molecular docking showed a stable interaction between the effective components of XMK and SREBP2 and NLRP3. Serum enzymology assays revealed the medication safety of XMK in cardiac, hepatic and renal function. Studies in vivo indicated that XMK improved serum lipids (TC, TG, LDL-C and HDL-C) and reduced plaque area. Body weight decreased, and the expression of inflammatory cytokines (IL-6, TNF-ɑ and VCAM-1) was inhibited. Then, XMK downregulated the mRNA and protein expression of SREBP2, NLRP3, ASC, IL-1β and Caspase-1. In vitro, the above findings were reinforced in BMDMs, and knocking down SREBP2 restrained the effect of XMK on the NLRP3/ASC/Caspase-1 signaling pathway. CONCLUSIONS: XMK restrains AS by improving inflammation through the SREBP2-mediated NLRP3/ASC/Caspase-1 signaling pathway.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Hou C, Jiang X, Sheng W, et al. Xinmaikang (XMK) tablets alleviate atherosclerosis by regulating the SREBP2-mediated NLRP3/ASC/Caspase-1 signaling pathway. J Ethnopharmacol. 2023. PMID: 37777030. doi:10.1016/j.jep.2023.117240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。